169 related articles for article (PubMed ID: 32768010)
1. The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors.
Wahl RL
Semin Nucl Med; 2020 Sep; 50(5):471-483. PubMed ID: 32768010
[TBL] [Abstract][Full Text] [Related]
2. Personalized Approaches to Gastrointestinal Cancers: Importance of Integrating Genomic Information to Guide Therapy.
He J; Ahuja N
Surg Clin North Am; 2015 Oct; 95(5):1081-94. PubMed ID: 26315525
[TBL] [Abstract][Full Text] [Related]
3. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
4. [Personalized tumor therapy for gastrointestinal tumors].
Ettrich TJ; Perkhofer L; Seufferlein T
Internist (Berl); 2015 Sep; 56(9):1069-78. PubMed ID: 26148698
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
6. Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors.
Yan W; Zhang A; Powell MJ
Chin J Cancer; 2016 Jul; 35(1):68. PubMed ID: 27443349
[TBL] [Abstract][Full Text] [Related]
7. Translating genomic profiling to gastrointestinal cancer treatment.
Harada K; Mizrak Kaya D; Shimodaira Y; Song S; Baba H; Ajani JA
Future Oncol; 2017 Apr; 13(10):919-934. PubMed ID: 28067073
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.
Lopez NE; Yeh JJ
Cancer Treat Res; 2016; 168():393-479. PubMed ID: 29206386
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
10. Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure.
Castagnoli F; Mencel J; Ap Dafydd D; Gough J; Drake B; Mcaddy NC; Withey SJ; Riddell AM; Koh DM; Shur JD
Radiographics; 2024 May; 44(5):e230047. PubMed ID: 38662587
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
12. The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors.
Halama N; Haberkorn U
Semin Nucl Med; 2020 Sep; 50(5):389-398. PubMed ID: 32768003
[TBL] [Abstract][Full Text] [Related]
13. Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: random or nonrandom, that is the question.
Lai BR; Wu YT; Kuo YC; Hsu HC; Chen JS; Chen TC; Wu RC; Chiu CT; Yeh CN; Yeh TS
Oncotarget; 2016 Dec; 7(50):83270-83277. PubMed ID: 27806309
[TBL] [Abstract][Full Text] [Related]
14. The Tipping Point: Key Oncologic Imaging Findings Resulting in Critical Changes in the Management of Malignant Tumors of the Gastrointestinal Tract.
Wu J; Goyal L; Nipp R; Wo J; Qadan M; Uppot RN
Curr Probl Diagn Radiol; 2019 Jan; 48(1):61-74. PubMed ID: 29674013
[TBL] [Abstract][Full Text] [Related]
15. Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal cancers of the microsatellite mutator phenotype.
Ohmiya N; Matsumoto S; Yamamoto H; Baranovskaya S; Malkhosyan SR; Perucho M
Gene; 2001 Jul; 272(1-2):301-13. PubMed ID: 11470537
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta signaling and its targeted therapy in gastrointestinal cancers.
Gotovac JR; Fujihara KM; Phillips WA; Clemons NJ
Discov Med; 2018 Sep; 26(142):103-112. PubMed ID: 30399328
[TBL] [Abstract][Full Text] [Related]
17. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.
Dhir M; Choudry HA; Holtzman MP; Pingpank JF; Ahrendt SA; Zureikat AH; Hogg ME; Bartlett DL; Zeh HJ; Singhi AD; Bahary N
Cancer Med; 2017 Jan; 6(1):195-206. PubMed ID: 28028924
[TBL] [Abstract][Full Text] [Related]
18. Computational Approaches for Diagnosis and Therapy of GI Malignancies.
Malla RR; Nammi D
Crit Rev Oncog; 2020; 25(4):301-310. PubMed ID: 33639059
[TBL] [Abstract][Full Text] [Related]
19. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
20. Screening in GI Cancers: The Role of Genetics.
Stoffel EM
J Clin Oncol; 2015 Jun; 33(16):1721-8. PubMed ID: 25918283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
